[In patients hospitalized for COVID-19 with hypoxia and systemic inflammation, does tocilizumab reduce 28-days mortality compared to standard treatment, and is it safe?] / Chez les sujets hospitalisés pour COVID-19 avec hypoxémie et inflammation systémique, est-ce que le tocilizumab diminue la mortalité à 28jours comparativement au traitement standard tout en étant sécuritaire ?
Rev Med Interne
; 42(7): 517-518, 2021 07.
Article
in French
| MEDLINE | ID: covidwho-1294189
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
French
Journal:
Rev Med Interne
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS